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Background and Purpose: Thrombolytics-induced recanalization fails in a significant portion of patients with 
ischemic stroke, which is partly due to the resistance of clots to lysis by thrombolytic agents. The pretreatment level 
of endogenous fibrinolysis inhibitors may affect such thrombolysis failure. 
Methods: We studied 43 stroke patients whose arterial recanalization had been evaluated by angiography, and 
whose blood had been obtained prior to the administration of thrombolytic agents. Plasma samples from 34 healthy 
volunteers were used as normal controls. Plasminogen activator inhibitor type 1 (PAI-1) and thrombin-activatable 
fibrinolysis inhibitor (TAFI) levels were quantified using an enzyme-linked immunosorbent assay. 
Results: Arteries were recanalized [Thrombolysis in Myocardial Infarction (TIMI) grade 2 or 3] in 30 patients, but 
not (TIMI grade 0 or 1) in the other 13. The plasma PAI-1 level was significantly higher in patients without 
recanalization (nonrecanalization) than in those with recanalization and in normal controls. The TAFI levels did not 
differ among the groups. 
Conclusions: The pretreatment PAI-1 levels are increased in acute stroke patients with thrombolysis failure.
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INTRODUCTION
Early and complete recanalization of an occluded 
artery is probably the most effective way to reduce 
mortality and neurologic deficits in acute stroke patients. 
Plasminogen activators such as tissue-type plasminogen 
activator (t-PA) and urokinase have been widely used to 
restore the blood flow to the ischemic brain, and have 
shown that they are effective in acute stroke patients.
1,2 
However, many patients still remain disabled because of 
hemorrhagic transformation as well as thrombolysis 
failure or deterioration after recanalization. Actually, it is 
known that recanalization is achieved in only 30-70% of 
stroke patients with thrombolytic treatment.
3
Few studies have examined the biomarkers that may 
be related to thrombolysis failure in stroke.
4,5 However, 
it is important to rapidly detect subjects who might be 
unsuitable for conventional fibrinolytic therapy prior to 
thrombolytic therapy because they may be managed with Kim SH, et al. Plasma Fibrinolysis Inhibitor Levels in Acute Stroke Patients with Thrombolysis Failure 
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an alternative or additive strategy such as platelet glyco-
protein IIb/IIIa receptor antagonists or mechanical clot 
removal.
6,7
The action of endogenous fibrinolysis inhibitors may 
influence the success or failure of clot lysis, and inter-
individual variation in the plasma levels of the fibrino-
lysis inhibitors may influence the individual suscepti-
bility to the fibrinolytic treatment. Although increased 
endogenous fibrinolytic inhibitor levels such as plasmi-
nogen activator inhibitor type 1 (PAI-1) are associated 
with thrombolysis failure and poor outcome in patients 
with acute myocardial infarction,
8 little is known about 
PAI-1 as a biomarker of thrombolysis failure in stroke 
patients. In this study, we examined the pretreatment 
plasma levels of two well-known endogenous fibrinolysis 
inhibitors, PAI-1 and thrombin-activatable fibrinolysis 
inhibitor (TAFI), and investigated their potential 
association with thrombolysis failure in acute stroke 
patients who receive thrombolytic treatment.
MATERIALS AND METHODS
1. Patients
Among a total 106 stroke patients who received 
thrombolytics over a 4-year period, 43 consecutive 
patients whose arterial recanalization could be evaluated 
by post-thrombolysis angiography (39 by catheter angio-
graphy, 3 by MR angiography, and 1 by CT angio-
graphy) and whose blood could be obtained before 
administering the thrombolytic agents were enrolled in 
this study. The exclusions were due to not performing 
angiography in 8 patients and the inability to obtain 
blood samples in 55 patients. The demographic charac-
teristics of sex and age, risk factors for stroke, laboratory 
data, and the initial National Institutes of Health Stroke 
Scale (NIHSS) score did not differ between the 43 
included and 63 excluded patients (P<0.05). Seventeen 
patients were treated with intravenous (IV) t-PA, 11 
with intra-arterial (IA) urokinase, and 15 with combined 
IV t-PA and IA urokinase. The indication and regimen 
for IV, IA, or combined IV and IA treatment, and the 
outcome measurements have been reported previously.
9,10 
Briefly, IV t-PA was indicated when the planned 
infusion could be initiated within 3 hours after symptom 
onset, and IA urokinase was administered to patients 
showing no early clinical responses to IV t-PA at the 
end of t-PA infusion or to those who could be treated 
within 3-6 hours after symptom onset. The institutional 
review board approved this study, and informed consent 
was obtained from the patient or the patient's represen-
tative.
The patency of the occluded arteries was assessed 
using the Thrombolysis in Myocardial Infarction (TIMI) 
grading system,
11 and the patients were grouped into 
nonrecanalization (TIMI grade 0 or 1) and recanalization 
(TIMI grade 2 or 3).
2. Blood sampling
On their arrival at hospital, blood was drawn from the 
patients into a heparinized tube at the time of the initial 
blood sampling for the emergent laboratory workup. 
Control blood samples were obtained from volunteers 
aged >40 years at the time of their annual institutional 
health examinations. The examinations included routine 
history taking, a physical examination, blood pressure 
measurements, chest x-ray, electrocardiography, and 
blood tests including hemoglobin, fasting sugar, and total 
cholesterol. Those with a previous history of hyper-
tension, diabetes, stroke, coronary artery diseases, inflam-
matory diseases, or malignancies were excluded. Those 
with a systolic blood pressure >140 mmHg, a diastolic 
blood pressure >90 mmHg, a fasting blood sugar >140 
mg/dl, or a total cholesterol >240 mg/dl were also 
excluded. The control blood samples were obtained from 
34 volunteers (17 men and 17 women) with a mean age 
of 48 years.
The blood samples obtained from the patients and 
volunteers were immediately refrigerated and centrifuged 
at 900Xg for 15 minutes at 4℃, and the plasma were 
then stored at -80℃  until analysis.
3. Measurement of plasma PAI-1 and TAFI levels
The PAI-1 and TAFI antigen levels were determined 
using a commercially available enzyme-linked immuno-Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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Nonrecanalization 
(N=13)
Recanalization 
(N=30)
P  value
Median age (range), years 66 (50-76) 67 (25-85) 0.99
Sex (men : women) 4:9 17 : 13 0.19
Risk factors, number (%)
Hypertension
Diabetes mellitus
Smoking
Previous stroke
Cardiac embolic sources
 8 (62)
 3 (23)
1 (8)
 3 (23)
 8 (62)
18 (60)
10 (33)
 9 (30)
 9 (30)
17 (57)
1.00
0.72
0.24
0.73
1.00
Laboratory data, median (range)
Hemoglobin, g/l
White blood cells, ×10
9/l
Blood sugar, mmol/l
Cholesterol, mmol/l
128 (93-171)
8640 (4590-14270)
7.16 (5.44-12.04)
4.53 (2.69-6.06)
139 (107-175)
8440 (5560-19050)
7.05 (2.55-18.54)
4.71 (3.16-6.79)
0.08
0.43
0.57
0.59
Involved arteries, number
Middle cerebral artery
Internal carotid artery
Basilar artery
Posterior cerebral artery
5
6
1
1
22
2
6
0
<0.01
Initial NIHSS score, median (range) 20 (13-33) 17 (4-30) 0.47
Thrombolysis methods, number
IV t-PA
IA Urokinase
IV t-PA+IA Urokinase
8
1
4
9
10
11
0.25
HT, number (%)  4 (31)  8 (27) 1.00
HT: hemorrhagic transformation, NIHSS: national institutes of health stroke scale, IV t-PA: intravenous tissue-type plasminogen activator, 
IA: intra-arterial.
For comparison between groups, the Mann-Whitney U test was used for age, laboratory data, and NIHSS score, and Fisher's exact test 
was used for sex, risk factors, involved arteries, and HT.
Table 1. Demographic characteristics of the patient groups
sorbent assay (ELISA) kit (Zymutest PAI-1 Ag and 
Zymutest TAFI Ag, Hyphen BioMed, Andresy, France) 
according to the manufacturer’s instructions.
4. Statistical analysis
The levels of plasma PAI-1 and TAFI were compared 
among the groups for significant differences using the 
Kruskal-Wallis test. The Mann-Whitney U test and 
Fisher’s exact test were used to compare the variables 
between the nonrecanalization and recanalization groups. 
Logistic regression was used to determine independent 
factors associated with the nonrecanalization group. The 
95% confident intervals (CIs) were calculated, and 
differences were considered statistically significant when 
P<0.05. Statistical analyses were performed with SPSS 
(version 10.0) software.
RESULTS
Recanalization was evaluated by conventional catheter Kim SH, et al. Plasma Fibrinolysis Inhibitor Levels in Acute Stroke Patients with Thrombolysis Failure 
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Figure 1. Plasma plasminogen activator inhibitor type 1 (PAI-1) (A) and thrombin-activatable fibrinolysis inhibitor (TAFI) (B) levels in
each group as measured by an enzyme-linked immunosorbent assay. The PAI-1 level was significantly higher in the nonrecanalization
group  (N-Rec) than in the normal control (NC) and recanalization (Rec)  groups. Medians and interquartile ranges are shown. 
angiography in 39 of the 43 enrolled patients. Among 17 
patients treated with IV t-PA, catheter angiography was 
performed for IA thrombolysis immediately after infusion 
of t-PA in 11 patients, but IA urokinase was not 
administered because the artery was occluded at the 
proximal carotid level (3 patients) or the artery was 
opened or occluded at the distal branch (8 patients). The 
remaining six patients received diagnostic investigations 
within 48 hours after symptom onset (two by catheter 
angiography, three by MR angiography, and one by CT 
angiography). The median time from symptom onset to 
angiography was 4 hours and 10 minutes. Recanalization 
was achieved in 30 of the 43 patients. An occlusion at 
the middle cerebral artery or the basilar artery was 
recanalized more often (P<0.01). Otherwise, there were 
no significant differences between the two groups in the 
risk factors for stroke, the initial laboratory data, the 
severity of the neurological deficits based on the initial 
NIHSS score, the thrombolysis method, and the 
frequency of hemorrhagic transformation (Table 1).
The plasma PAI-1 and TAFI levels, which were 
measured by ELISA, were compared between the two 
thrombolytics-treated groups and the controls. The time 
interval from symptom onset to blood sampling did not 
differ between the two thrombolytics-treated groups 
(medians of 98 minutes and 80 minutes in the non-
recanalization and recanalization groups, respectively; 
P=0.84). The PAI-1 levels differed significantly among 
the three groups, and was highest in the nonrecanali-
zation group: medians of 45.2 ng/ml (interquartile range 
[IQR], 32.5-50.0 ng/ml), 33.1 ng/ml (IQR, 24.9-38.1 
ng/ml), and 23.6 ng/ml (IQR, 17.5-37.5 ng/ml) in the 
nonrecanalization, recanalization, and control groups, 
respectively (P=0.007) (Fig. 1-A). However, the TAFI 
levels did not differ significantly among the groups 
(P=0.097) (Fig. 1-B).
Logistic regression showed that only the plasma 
PAI-1 levels were independently associated with 
recanalization (odds ratio, 0.916; 95% CI, 0.844-0.994).
DISCUSSION
In this study, the plasma PAI-1 levels were higher in 
patients with acute stroke, and higher pretreatment 
plasma PAI-1 levels were associated with thrombolysis 
failure. But the plasma TAFI levels did not differ 
between the control and patient groups. One study 
showed that increased plasma PAI-1 levels predicted clot 
lysis resistance in stroke patients treated with t-PA.
12 In 
that study, evidence of successful thrombolysis was 
based on transcranial Doppler investigations, which is 
consistent with our determination of the success or 
failure of thrombolysis in a more definitive and direct 
manner by angiography.
PAI-1 is reportedly increased in blood obtained within 
1-7 days after symptom onset in acute stroke patients.
13-15 
The findings in the present study further demonstrate Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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that plasma PAI-1 levels are increased during the very 
early stage of stroke, because all samples were obtained 
from patients who were eligible for thrombolytic therapy. 
T-PA is rapidly neutralized by PAI-1, which binds to the 
active site of t-PA and forms inactive complexes.
16,17 
Therefore, the presence of a pretreatment plasma PAI-1 
in excess of endogenous and/or exogenous t-PA or 
urokinase may depress their fibrinolytic activity.
17
The thrombus composition has been suggested as one 
of the important causes of thrombolytic resistance, and 
platelet-rich thrombi are disposed to resistance to throm-
bolysis.
18,19 Possible sources of increased PAI-1 in acute 
stroke are the endothelium, atherosclerotic plaques, and 
platelets, which are major sources of circulating PAI-1.
16 
The latent PAI-1 in alpha-granules of platelets is 
converted into the active form and is released upon 
platelet activation and aggregation. Therefore, large 
amounts of active PAI-1 are released from fresh platelet- 
rich thrombi, which contribute to the thrombolytic 
resistance.
17,20 In a murine carotid injury model that 
induced platelet-rich thrombi in wild-type and PAI-1- 
deficient mice, PAI-1 was found to be a major determi-
nant of the resistance of platelet-rich arterial thrombi to 
lysis by t-PA.
21 In contrast, the inactivation of PAI-1 
using a monoclonal antibody against PAI-1 accelerated 
the lysis of the platelet-rich thrombi in the mesenteric 
arteriole of rats.
12 All these findings indicate an important 
role of PAI-1 in inducing resistance to thrombolytics via 
platelet-mediated mechanisms, and suggest that an 
increased plasma PAI-1 level can be used as a 
biomarker for the prediction of thrombolysis failure in 
stroke patients.
Although TAFI acts as a fibrinolytic inhibitor, the 
plasma TAFI levels were neither increased in stroke 
patients nor associated with thrombolysis failure. Previous 
studies on coronary artery disease are also contro-
versial.
22  It has been suggested that, in contrast to PAI-1, 
genetic factors are much more important determinants of 
the plasma TAFI levels than environmental factors,
23 
which may explain the absence of an elevated plasma 
TAFI in the present study.
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